Alixorexton Phase 2 Trial Shows Positive Results for Narcolepsy Type 1

Alkermes' Vibrance-1 Phase 2 study of alixorexton for adults with narcolepsy type 1 demonstrated robust efficacy. Published in The Lancet Neurology, the data showed improvements in wakefulness, excessive daytime sleepiness, cataplexy, cognition, and fatigue, alongside a generally well-tolerated safety profile. These positive results advance the potential for a new once-daily treatment option for narcolepsy patients.